Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

PCR Biosystems kit for Illumina NGS systems

December 2020—PCR Biosystems has introduced its NGSBIO Library Quant Kit for Illumina. The kit contains all the components necessary for accurate and sensitive quantification of DNA libraries prior to next-generation sequencing with Illumina platforms. The kit contains five DNA standards, primers specific to the p5 and p7 Illumina adapter sequences, a library dilution buffer, and qPCRBIO SyGreen Mix or qPCRBIO SyGreen Blue Mix. The blue qPCR mix contains a nonreactive dye to improve reaction mix visibility and is useful when using small reaction volumes or white plates.

SARS-CoV-2 assay for BD Veritor Plus gets CE mark

December 2020—BD announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor Plus system has been CE marked to the IVD directive. The test delivers results in 15 minutes and has been authorized by the FDA under an EUA for use by authorized laboratories.

Agena granted EUA for SARS-CoV-2 panel

December 2020—Agena Bioscience’s MassArray SARS-CoV-2 Panel for qualitative detection of the SARS-CoV-2 coronavirus has been granted emergency use authorization from the FDA.

FDA approves liquid biopsy NGS CDx

December 2020—The FDA approved the Guardant360 CDx assay (Guardant Health), a liquid biopsy companion diagnostic that also uses next-generation sequencing technology to identify patients with specific types of mutations of the epidermal growth factor receptor gene in a deadly form of metastatic non-small cell lung cancer. This is the first approval to combine NGS and liquid biopsy in one diagnostic test in order to guide treatment decisions.

FDA issues EUA for saline oral rinse COVID-19 test

December 2020—OralDNA Labs announced that the FDA issued an amended emergency use authorization for the OraRisk COVID-19 RT-PCR test, allowing testing from a saline oral rinse collection. Samples are viable for up to 72 hours and do not require cold pack transportation.

Genalyte rapid COVID-19 antibody test obtains EUA

December 2020—Genalyte announced that its SARS-CoV-2 Multi-Antigen Serology Panel received emergency use authorization from the FDA. The panel tests for IgM and IgG antibodies against 13 unique viral antigens and runs on the company’s Maverick diagnostic system, which provides results in 20 minutes. The test demonstrated 98 percent specificity and 96 percent sensitivity.

Qiagen launches NeuMoDx multiplex test

December 2020—Qiagen announced the European launch of the NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Test, which aims to help health care professionals identify and differentiate between patients with common seasonal respiratory infections and COVID-19. The multiplex PCR test detects and differentiates influenzas A and B, respiratory syncytial virus, and SARS-CoV-2 infections within 80 minutes.

Eppendorf adjustable spacing pipettes

December 2020—Eppendorf released its Move It Adjustable Spacing Pipettes. Move It was designed for the synchronous pipetting of a series of samples between different vessel formats, such as between tubes and plates, without tubing connections between cone and piston-cylinder system. The format of microplates can be adjusted directly with the format limiters. For other sample tubes or tubes in holders, the cone spacing is selected by using the rotary knob.

Magnolia launches Mission to Zero

November 2020—Magnolia Medical Technologies launched Mission to Zero to bring greater awareness to patient safety and antibiotic-associated risks caused by false-positive diagnostic test results for sepsis. Magnolia is launching the initiative by partnering with emergency departments, critical care units, clinical laboratories, and infection prevention teams within acute care hospitals. Each team member makes an individual pledge to participate, the company says, which allows all departments to work in tandem to ensure the best possible patient outcomes and experience are achieved.

MARKETPLACE

TRENDING